News Sentiment

LYEL sentiment intelligence

Lyell Immunopharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.01 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+6.8% over one week, +11.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Form S-3 Lyell Immunopharma Inc For: 13 July By Investing.com

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction 6.8% Price confirming higher
Trend fit Trend inactive 11.2% over four weeks
Fair value -42.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 36
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 9
Investing.com 4
TradingView 4
GlobeNewswire 4
simplywall.st 3
MT Newswires 2
Investing.com South Africa 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 13
Analyst action 3
Deals and strategy 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
Investing.com Nigeria Direct company coverage

Form S-3 Lyell Immunopharma Inc For: 13 July By Investing.com

This article announces that Lyell Immunopharma Inc. filed a Form S-3 on July 13. The filing is brief and includes a stock performance update for LYEL, which was down 4.53%. The text also contains various financial market data and unrelated popular news.

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 00:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Lyell Immunopharma (NASDAQ: LYEL) files resale shelf for 1.1M shares

Lyell Immunopharma (NASDAQ: LYEL) has filed an S-3 shelf registration statement for the resale of up to 1.1 million shares of common stock by Innovative Cellular Therapeutics Holdings Limited (ICT Holdings). Lyell will not receive any proceeds from these sales, which stem from an

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:43
Source
Stock Titan
Ad-hoc-news.de Direct company coverage

Lyell Immunopharma updates pipeline strategy as cell therapy field evolves

Lyell Immunopharma is refining its cell therapy pipeline and manufacturing approach to enhance T cell function and persistence in treating solid tumors. The company focuses on addressing T cell exhaustion and dysfunction, aiming to compete with other immuno-oncology modalities. A

Tone
Positive 63/100
Event
Market update
Published
03 Jul 2026 14:58
Source
Ad-hoc-news.de
Finviz Direct company coverage

LYEL - Lyell Immunopharma Inc Volatility & Greeks

This article provides a detailed financial overview of Lyell Immunopharma Inc (LYEL), including its stock performance, key financial metrics, volatility indicators, and ownership data. It presents a snapshot of the company's market capitalization, income, sales, earnings per shar

Tone
Negative 41/100
Event
Earnings
Published
02 Jul 2026 17:40
Source
Finviz
Investing.com South Africa Direct company coverage

Form 4 Lyell Immunopharma Inc For: 1 July By Investing.com

This article reports a Form 4 filing for Lyell Immunopharma Inc. on July 1st, highlighting the company's stock symbol LYEL. It notes a 4.55% increase for the stock, indicating recent market activity for the company.

Tone
Positive 74/100
Event
Market update
Published
01 Jul 2026 17:14
Source
Investing.com South Africa
Stock Titan Direct company coverage

Innovative Cellular Therapeutics moves 76K Lyell (LYEL) shares as broker commission

Innovative Cellular Therapeutics Holdings Ltd, a major shareholder of Lyell Immunopharma, Inc., transferred 76,000 shares of Lyell common stock to Wuxiong, Inc. as a broker commission related to an upfront payment under a license agreement. This "other" transaction, which involve

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 16:09
Source
Stock Titan
TradingView Direct company coverage

Lyell Immunopharma, Inc. Actuals & Estimates (NASDAQ:LYEL)

This article provides an overview of Lyell Immunopharma, Inc. (NASDAQ: LYEL) stock performance, financial estimates, and analyst forecasts. It includes details on recent price changes, volatility, market capitalization, earnings reports, and future revenue and earnings prediction

Tone
Negative 42/100
Event
Earnings
Published
26 Jun 2026 02:39
Source
TradingView
TradingView Direct company coverage

LYEL Forecast — Price Target — Prediction for 2027

This article provides a detailed forecast and price target for Lyell Immunopharma, Inc. (LYEL) stock, incorporating analyst opinions, historical performance data, and financial metrics. It covers various aspects including current stock price, volatility, market capitalization, ea

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 23:11
Source
TradingView
Intellectia AI Direct company coverage

LYEL Financials: Revenue Breakdown, Margins & Competitor Comparison

This article provides a financial overview of Lyell Immunopharma Inc (LYEL), detailing its revenue breakdown, profitability margins, and a comparison with competitors. LYEL maintains a gross margin of 100.00% but reports negative operating and net margins, indicating challenges i

Tone
Negative 30/100
Event
Earnings
Published
25 Jun 2026 23:09
Source
Intellectia AI
Investing.com Canada Direct company coverage

Form 4 Lyell Immunopharma Inc For: 24 June By Investing.com

The article reports on a Form 4 filing for Lyell Immunopharma Inc. dated June 24. This filing is related to insider trading information for the company (ticker: LYEL), which saw a 2.93% increase in its stock price. The content is presented by Investing.com, a financial markets pl

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 16:09
Source
Investing.com Canada
Stock Titan Direct company coverage

Innovative Cellular Therapeutics (LYEL) crosses 12.3% ownership after milestone

Innovative Cellular Therapeutics Holdings Limited has reported beneficial ownership of 3,000,000 shares of Lyell Immunopharma (LYEL) common stock, representing approximately 12.3% of the class. This increase in ownership, detailed in an amended Schedule 13G/A filing, occurred aft

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 20:32
Source
Stock Titan
Stock Titan Direct company coverage

Innovative Cellular Therapeutics (LYEL partner) reports 3M Lyell Immunopharma shares

Innovative Cellular Therapeutics Holdings Ltd has filed an initial statement of beneficial ownership, reporting a holding of 3,000,000 common shares of Lyell Immunopharma, Inc. This stake arises from a License Agreement between the two companies, with 1.9 million shares received

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Lyell Immunopharma (LYEL) major holder transfers shares as commission

Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma (LYEL), transferred 66,500 shares of common stock to LifeSci Advisors, LLC as broker commission on June 15, 2026. This transfer, made for no cash consideration, was tied to an upfront payment under a

Tone
Neutral 50/100
Event
Balance sheet
Published
18 Jun 2026 01:40
Source
Stock Titan
TradingKey Direct company coverage

Lyell Immunopharma Inc (LYEL) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Lyell Immunopharma Inc (LYEL), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that Lyell's score is 7.67, ranking 276 out of 388 in the Biotechnology & Medical Research industr

Tone
Positive 74/100
Event
Earnings
Published
17 Jun 2026 21:09
Source
TradingKey
Investing.com Direct company coverage

Lyell Immunopharma president and CEO Lynn Seely sells $7,337 in stock

Lyell Immunopharma's CEO, Lynn Seely, sold 388 shares worth $7,337, a transaction primarily to cover tax obligations from vested restricted stock units. This occurs as LYEL shares have experienced recent volatility, with a 10% gain over the last week but a 58% decline over six mo

Tone
Positive 61/100
Event
Market update
Published
16 Jun 2026 09:09
Source
Investing.com
Investing.com Direct company coverage

Lyell Immunopharma COO Stephen Hill sells $1,683 in shares

Stephen J. Hill, COO of Lyell Immunopharma (NASDAQ:LYEL), sold 89 shares totaling $1,683 on May 11, 2026, to cover tax obligations from vested restricted stock units. The sale occurred at an average price of $18.92 per share, significantly above the current stock price of $13.55,

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 09:09
Source
Investing.com
Investing.com South Africa Direct company coverage

Lyell Immunopharma CSO Gary K. Lee sells $2,459 in LYEL stock By Investing.com

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, sold $2,459 worth of LYEL stock on May 11, 2026, to cover tax obligations from vested restricted stock units. Following this, he still holds 17,808 shares. The sale occurred while the biotech company, valued at $315 mill

Tone
Positive 66/100
Event
Market update
Published
15 Jun 2026 23:10
Source
Investing.com South Africa
Stock Titan Direct company coverage

Lyell Immunopharma (LYEL) CEO’s 388-share tax-related stock sale detailed in Form 4

Lyell Immunopharma (LYEL) CEO Lynn Seely reported a sale of 388 shares of common stock on May 11, 2026, at a weighted average price of $18.91 per share. This transaction was an automatic sale to cover tax withholding obligations from vested restricted stock units, not a discretio

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Lyell Immunopharma (LYEL) CSO reports small tax-driven sale of company shares

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, reported a sale of 130 company shares at a weighted average price of $18.92 per share. This transaction was an automatic sale to cover tax withholding obligations associated with vested restricted stock units, not a disc

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Lyell Immunopharma (LYEL) VP auto-sells shares to cover RSU tax withholding

Veronica Sanchez Bulis, VP and Corporate Controller of Lyell Immunopharma (LYEL), automatically sold 217 shares of company common stock on May 11, 2026. This sale was conducted to cover tax withholding obligations arising from the settlement of vested restricted stock units. Foll

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Lyell Immunopharma (LYEL) COO’s 89-share sale tied to RSU tax withholding

Lyell Immunopharma's Chief Operating Officer, Stephen J. Hill, reported an automatic sale of 89 shares of common stock on May 11, 2026, at a weighted average price of $18.92 per share. This sale was conducted to cover tax withholding obligations associated with the vesting of res

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Lyell Immunopharma (NASDAQ: LYEL) reports 2026 shareholder meeting and director elections

Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the results of its 2026 annual meeting, where shareholders elected three directors—Richard Klausner, M.D., Otis Brawley, M.D., and William Rieflin—with significant support. A quorum was established with 67.31% of outstanding share

Tone
Neutral 50/100
Event
Earnings
Published
15 Jun 2026 20:10
Source
Stock Titan